Paranoia Over Virus Research May Have Brought Gagandeep Kang, US CDC Officials on to Snoop List

It may not be a coincidence that some of the people in healthcare targeted for potential surveillance were also involved with the Nipah virus outbreak in some capacity.

New Delhi: On May 19, 2018, the state of Kerala reported a major outbreak of the Nipah virus. This was scary for a few reasons: its mortality rate is high, it has no known vaccine or definitive treatment, and because the outbreak began suddenly. However, Kerala’s clinical research and healthcare system emerged as a hero. Researchers quickly identified the outbreak as being due to the Nipah virus – a feat that experts have likened to “pulling a rabbit out of a hat” – and then the state machinery mounted a successful disease surveillance programme.

To help deal with future outbreaks better, Gagandeep Kang had requested the Indian Council of Medical Research (ICMR) at the time to share blood samples of the few Nipah survivors for research supported by the Coalition for Epidemic Preparedness Innovations (CEPI), a foundation based in Norway. Specifically, Kang – as a member of the CEPI board – requested government officials to share samples with the International Centre For Genetic Engineering And Biotechnology, New Delhi, or the Translational Health Science And Technology Institute, Faridabad (the samples couldn’t leave the country).

Kang told The Wire Science that these institutes “were the only places in India with the ability to do the work needed for exploring antibody repertoires from Nipah survivors.”

However, ICMR didn’t entertain the request, despite – she told the Pegasus Project – her appeals to Department of Biotechnology secretary Renu Swarup and principal scientific adviser K. VijayRaghavan.

CEPI later separately established a successful collaboration with icddr,b in Bangladesh, which follows more survivors of Nipah.

Surveillance target

These incidents encompass the major events that happened in 2018, when the name of Gagandeep Kang – today a household name because of her work on the SARS-CoV-2 virus – entered a list of phone numbers created by an unidentified Indian entity as a person of interest in June that year. Some of the 300 phone numbers on the list that The Wire was able to verify turned out to have been targeted and infected by Pegasus spyware in the period 2017-2019.

Over the past few days, The Wire and 16 media organisations around the world have been publishing information about Pegasus’s intended targets. Forbidden Stories, a French non-profit, was able to access the database, and together with its media partners, has worked with Amnesty International and CitizenLab to ascertain its contents.

Pegasus is the name of software developed by the Israeli firm, NSO Group. NSO has said in official statements since July 18 that it sells Pegasus only to governments that it has vetted. As such, the attempts to surveil various people with Pegasus are believed to be the handiwork of their respective governments. To date, neither NSO nor the Indian government have denied that the Indian government is a Pegasus user.

In an interview to the Pegasus Project, Kang said:

“… there were discussions around Nipah in an international meeting being convened around August of 2018. Other than that, we weren’t working on anything particularly controversial. I was [trying] to get the funding for the CEPI lab to be established and stuff like that. So I can’t think of anything other than CEPI. I’ve worked with the same partners – [US] National Institutes of Health, WHO, Gates Foundation kind of stuff throughout, so there was nothing special other than Nipah that was happening at that time.”

Kang also said that at the time, in 2018, she had been working on the rotavirus as well but called it “hardly controversial”.

Nipah virus research

While a full forensic examination of the phone she was using at the time – the only way to conclusively determine it it was targeted or infected – could not be conducted, and an SMS application check (one of a few checks) turned up negative, there is circumstantial evidence to believe the attempt to surveil Kang is linked to the Nipah virus outbreak.

Around the same time, between April and July 2018, the name of another individual shows up as having been selected for potential surveillance. This individual, who did not consent to being named, was involved in a collaboration that included the Manipal Centre for Virus Research (MCVR), Karnataka, to monitor the Nipah outbreak.

An Appeal: Support Investigative Journalism That Brings You The Truth. Support The Wire.

In February 2020, India’s health ministry alleged that MCVR, which had a reputation for conducting important research on infectious diseases, was storing Nipah virus samples without the proper safeguards. Officials from the same ministry also alleged, according to a media report, that the facility was running a multi-year fever surveillance project with funds from the US Centres for Disease Control (CDC), without the Indian government’s permission.

Also of relevance is the fact that the telephone number of an official working with the  CDC was also placed on the Indian list of persons of interest around the same time as Kang. Another CDC official, an American national stationed in India at the time, was also added to the list before the Nipah outbreak, as was the head of a health-sector nonprofit, suggesting the Indian agency responsible for selecting the numbers may have had a broader interest in the US public health agency. The Wire and its media partners have verified the identities of the individuals operating these three numbers but are withholding their names at their request.

Arunkumar Govindakarnavar, the head of the project at MCVR, told The Wire Science “that his lab had transferred all Nipah samples to the ICMR in July 2018 – soon after Kerala’s first Nipah outbreak concluded” and that “the ICMR and the health ministry had been closely involved in reviewing the fever project since its inception in 2014”. The Wire Science also found that at least one paper published in 2018 about the Nipah outbreak listed top scientists of the MCVR, the ICMR and the National Centre for Disease Control, under the health ministry, among its authors.

According to this paper, MCVR was able to help identify the Nipah virus so quickly – pulling the rabbit out of the hat – thanks to the CDC’s training. But after the health ministry’s allegations in early 2020, MCVR lost its FCRA license (required to receive money from foreign entities) and shut Govindakarnavar’s lab.

Since then, the collaboration has become defunct; the unnamed individual later joined a private foundation and currently helps with its COVID-19 response in India.

Kang’s efforts to have the ICMR share blood samples of Nipah survivors eventually went nowhere. “I was talking to a bunch of people who were interested in trying to figure out what we could best do for Nipah,” she told the Pegasus Project.

Kang added that Manoj Murhekar, head of the National Institute of Epidemiology, had also expressed cynicism about her efforts. Eventually, she said, “it was just conversations, it didn’t go anywhere.”

Hard to collaborate

It may not be a coincidence that some of the people in healthcare targeted for potential surveillance were also involved with the Nipah virus outbreak in some capacity, especially considering two major recent incidents in which the government has vilified scientific work involving foreign collaborators.

One of course was the MCVR incident, as a result of which the facility disappeared from India’s COVID-19 response, despite still being one of the country’s top research facilities vis-à-vis infectious diseases, and Govindakarnavar lost his job. The other involved the National Centre for Biological Sciences (NCBS), Bengaluru, which butted heads with the ICMR over a study of bats in Nagaland from 2012.

Also read: From Ambedkarites and Labour Activists to Umar Khalid and JNU Students, Snoop List Targets All

In late 2019, two months after the study was published, the cabinet secretary informed the Tata Institute of Fundamental Research (TIFR), Mumbai, that the ICMR had launched an investigation into the study. TIFR oversees NCBS; both institutes come under the Department of Atomic Energy.

In this study, NCBS researchers had travelled to Nagaland, where they had collected blood samples from locals who had recently come in contact with bats in a cave, and blood and tissue samples from the bats. In their paper, published in October 2019 in the journal PLoS Neglected Diseases, the researchers wrote that they had been able to match antibodies in the blood samples to three filoviruses hosted in the bats’ bodies.

News reports in February 2020 quoted unnamed officials in the government as alleging that the NCBS researchers hadn’t secured the requisite permissions and that they had potentially exposed “Indian biological specimens and cultural knowledge” to the influence of the Chinese government and the US army.

Those fanciful allegations echo the unfounded fears fanned by the health ministry in 2018 that the Nipah virus, by virtue of being so deadly, could be turned into a bioweapon and that, allegedly by being careless, the MCVR was risking this outcome.

A source familiar with the proceedings had told The Wire Science that the NCBS researchers had approached the National Institute of Virology, Pune, which is administered by the ICMR, to collaborate on their study, but that the institute wasn’t interested. The ICMR’s report of its investigation had yet to be published as of early June this year.

It was additionally unclear why the ICMR – a medical research body – was handling an investigation of a study that required expertise in ecological research (into microbes present in wild animals). More recently, and in similar vein, the Indian government tasked the ICMR with qualifying private facilities to test for COVID-19 – a topic on which it has no expertise, and a choice that led to a flood of quality complaints.

As things stand, collaborative research is already difficult in India, where scientific work is highly compartmentalised. Ongoing collaborations are also limited to a small subset of a larger number of institutes – and, among them, to those that have managed to obtain regulatory approvals from multiple authorities. If the government is determined to further disincentivise team-work – especially international collaborations to tackle public health threats that do not recognise national borders – then Prime Minister Narendra Modi’s exhortation at the G7 summit last month that the world must deal with the COVID-19 pandemic through a “One Earth, One Health” approach, has no meaning.

Joanna Slater of The Washington Post interviewed Dr Gagandeep Kang for the Pegasus Project.

Read The Wire’s coverage as part of the Pegasus Project here.

Home Ministry Revokes Manipal University’s FCRA License Over Nipah Study

An unnamed ministry official reportedly said the license had been cancelled in January 2020 and the university had been informed.

In a surprising move, the Ministry of Home Affairs has suspended Manipal University’s FCRA license, effectively stopping the institute from availing or using foreign funds, citing “unauthorised” research undertaken by the Manipal Institute of Virology, according to Hindustan Times.

FCRA stands for the Foreign Contribution Regulation Act of 2010, which regulates the use of funds transferred across the border.

The accusation pertains to the Manipal Centre for Virus Research’s (MCVR’s) actions during the Nipah virus outbreak in Kerala in 2018. The Indian Council of Medical Research and the Union health ministry had accused the lab of storing and studying Nipah samples in a lab that didn’t have the necessary safeguards to contain the virus, and going so far as to suggest the lab’s access to foreign funds had potentiated it to develop bioweapons.

However, MCVR has strongly denied these allegations, explaining that the ministry had explicitly approved the lab to handle Nipah samples as well as that the lab had inactivated the virus, thus nixing its ability to infect, before studying it.

An unnamed ministry official reportedly said the license had been cancelled in January 2020 and the university had been informed. Prior to this incident, the government had also terminated the Acute Febrile Illness Project, which the MCVR and the US Centres for Disease Control had been working on together to study numerous infectious diseases with no known treatment, including the Nipah and Ebola viruses, citing the same reasons.

Also read: As Paranoia Goes Viral in Govt Health Circles, Testing Labs Face the Heat

Additionally, Arunkumar Govindakarnavar, the director of the MCVR, told Hindustan Times, “The university has not used any foreign contribution for Nipah testing. In addition, the university has filed reports on the use of foreign funding every 15 days. All account details have been provided.”

So in both cases, the two ministries – of health and home affairs – appear to have acted based on a single episode whereas MCVR has said the government has always been in the loop. The Wire itself was able to verify that the health ministry had been receiving regular updates about MCVR’s activities vis-à-vis the Nipah virus. As Priyanka Pulla wrote,

From publicly available documents, it is clear that both ICMR and India’s National Centre for Disease Control (NCDC), an institute under the Union health ministry, were aware of MCVR’s Nipah testing capabilities and the minutiae of the fever project. A 2018 paper published in the journal BMJ Global Health and coauthored, among others, by Balram Bhargava, director general (DG) of ICMR; Sujeet Singh, director of NCDC; Promila Gupta, principal consultant at the Directorate General of Health Services (a health ministry body); and Govindakarnavar stated that the Manipal centre’s ability to test the Nipah virus helped Kerala respond quickly to the unprecedented 2018 outbreak.

The government’s decision to suspend Manipal University’s FCRA license is doubly surprising because educational and research institutions are rarely subject to such punishment, especially on the back of singular events.

Coronavirus: India to Evacuate Citizens From Wuhan on Friday

There will be another flight subsequently which will carry those who are from other parts of Hubei province.

Beijing: India is preparing to evacuate its citizens on Friday from China’s Wuhan city, the epicentre of the deadly coronavirus that has killed 170 people, infected 7,711 others and spread to at least 17 countries.

India earlier requested China for permission to operate two flights to bring back its nationals from worst-affected central Hubei province. Wuhan is the provincial capital of Hubei.

In a big relief for Indians – mostly students and professionals – stranded in Wuhan, the Indian Embassy in a note circulated through social media on Thursday said that preparations are on to evacuate them from the virus-hit region.

“We are preparing for air evacuation from Wuhan tomorrow in the evening. This flight will carry those Indian nationals who are in and around Wuhan and have conveyed consent for their evacuation,” the note said.

“There will be another flight subsequently which will carry those who are from other parts of Hubei province,” it added.

The Indian government and the Indian Embassy here have been collecting requisite details of the stranded Indians and held talks with the Chinese Foreign Ministry to work out the modalities for their evacuation.

Also read: Why India Should Worry About the New Coronavirus

The exact number of Indians stranded in Hubei has not yet been revealed.

“Please note that these details are tentative and are being shared with you so that you are adequately prepared,” the note said.

“We would request your understanding and cooperation. Our intention is to ensure that all those who have expressed consent to avail this facility are safely returned to India. We will shortly update you and send further instructions, it said.

According to reports, an Air India 747 Boeing has been kept ready to fly them back to India.

The embassy has already informed the stranded Indians that upon their arrival in India they need to undergo a 14-day quarantine in a designated city, the name of it which has not yet been revealed.

The quarantine was necessary as experts say the incubation period of the new virus was on average three to seven days, with the longest being 14 days.

The Indian embassy has opened three hotlines to help the Indians in Wuhan to cope up with the crisis.

Besides India, several other countries including the US, France, Japan, South Korea, are airlifting their nationals from Wuhan.

A large number of people from Pakistan, Sri Lanka, Bangladesh from the neighbourhood besides African countries were also reportedly stranded in Hubei province.

The nationwide death toll from novel coronavirus has jumped to 170 with 38 more fatalities reported mainly from Hubei province, the government said on Thursday, while confirming more than 1,700 new infections.

China’s National Health Commission said on Thursday that 7,711 confirmed cases of pneumonia caused by the novel coronavirus had been reported in 31 provincial-level regions and in the Xinjiang Production and Construction Corps by the end of Wednesday.

Why India Should Worry About the New Coronavirus

When novel viruses like the 2019 nCoV appear, there is a high risk of a pandemic – a chain of transmission that envelopes the world.

Note: This story was updated on January 31, 2020, at 10:35 am to reflect new evidence that the 2019 nCoV can be transmitted by asymptomatic patients.

China’s coronavirus outbreak, which began in December 2019, has now spread to 14 countries. Dubbed the 2019 novel coronavirus – 2019 nCoV – by the World Health Organisation (WHO), it has thus far infected 4,593 and killed 106 people.

India is worried too. The Union health ministry has said in recent press releases that it is taking numerous steps to prevent the virus from spreading to India. Key among them is an air-traveller screening program. Till January 27, the ministry said, 29,707 patients had been screened for fever at Indian airports. Of them, samples of 12 passengers, who presumably had symptoms of pneumonia, were sent to the National Institute of Virology. None of these people have tested positive for the novel coronavirus, the ministry said.

Why must India be wary of the coronavirus? And how big is the outbreak likely to get? Read on to find out.

What is novel about this coronavirus?

Coronaviruses get their name from the crown-like circle of spikes they display under a microscope. Six coronaviruses are already known to trigger disease in humans: the Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS) among them are the newest and most well-known. Both SARS, discovered in 2003, and MERS, discovered in 2012, caused major epidemics around the world. But these were successfully contained. And India seems to have dodged both of them (as attested here and here), not having reported any confirmed cases.

The other four coronaviruses have been around for much longer. And there is evidence of some of them, like the human coronavirus 229E and the human coronavirus HKU1, circulating in India. These viruses also mainly cause respiratory illness, like SARS and MERS. But their symptoms are typically milder, like a common cold, says Arunkumar Govindakarnavar, a virologist at Karnataka’s Manipal Institute of Virology.

Enter the 2019 novel coronavirus – first detected in the Chinese city of Wuhan in December 2019. After it caused a cluster of pneumonia cases in the city, scientists sequenced its genome and realised it was a brand new member of the coronavirus group. This means humans lack immunity to it, making it liable to spread quickly in human populations.

When novel viruses like the 2019 nCoV appear, there is a high risk of a pandemic – a chain of transmission that envelopes the world. Recall the 2009 emergence in the US of the H1N1 influenza subtype, thought to have jumped to humans from pigs. The virus subsequently became efficient at transmitting among humans, just like the Wuhan coronavirus has. This led to large waves of disease across the world in 2009 and 2010. Eventually, H1N1 spread to every country in the world and now causes regular outbreaks of seasonal flu.

If a seasonal flu sounds better than pandemic flu, it isn’t. As a recurrent illness, H1N1 has killed around 7,000 people in India since 2011, when the so-called post-pandemic phase began. The year 2017 alone witnessed 38,811 Indians being infected, with 2,270 dead.

H1N1’s trajectory illustrates how an explosive pandemic can leave a trail of morbidity even after it dies down. If the 2019 nCoV follows the same trajectory, it could well establish itself as an endemic disease in India, like H1N1 has, says Govindakarnavar. With a large burden of endemic diseases to deal with already – whether malaria, H1N1, dengue or tuberculosis – India could certainly do without one more.

What are the chances that the 2019 nCoV will come to India?

In a highly interconnected world, the chances are very high. Through a note published on January 22, researchers from the UK’s Imperial College London estimated that 3,301 people flew out of Wuhan’s airports every single day in the last two months. Already, such travel has precipitated two cases of 2019 nCoV in India’s neighbours, Nepal and Sri Lanka. So India’s program to thermally screen incoming travellers is a good move.

But it may not be enough. This is because there are hints that the 2010 nCoV can be transmitted even by patients with no symptoms like fever. In a paper published last week, researchers from Shenzhen described the case of a 10-year-old boy who was infected with the virus but showed no symptoms. His family members had contracted the virus on a visit to Wuhan and had requested the doctors to test the boy too. It was only after the boy was put through a CT scan that his lungs showed characteristic changes related to nCoV pneumonia. However, even though the boy was shedding the virus, it wasn’t clear if he had transmitted the virus to anyone else.

A subsequent correspondence in the New England Journal of Medicine on January 30 bolstered the case for asymptomatic transmission further. Here, German researchers reported that a Munich businessman seemed to have contracted the virus from his colleague from Shanghai, a businesswoman travelling to Munich. The Shanghai resident had been well during her visit, but fell ill on her flight back to China. When tested, she was positive for the nCoV. This led to her colleagues in Munich being examined as well, revealing that the Munich businessman, as well as three of his colleagues, had contracted the virus.

“The fact that asymptomatic persons are potential sources of 2019-nCoV infection may warrant a reassessment of transmission dynamics of the current outbreak,” the authors of the correspondence wrote.

This ability to spread asymptomatically could make the nCoV hard to control because it means that infectious people may get past screening programs. In contrast, SARS was mainly transmitted by sick patients; in fact, most infections occurred in hospitals where these patients had been admitted. This allowed SARS to be controlled through hospital-based measures, something that isn’t possible here.

If the coronavirus does come to India, how bad can it get?

As of now, the coronavirus seems to be killing around 3% of those it infects – a number known as the case fatality ratio. This makes it look much better than SARS, which killed 9.6% of the people it infected globally, and MERS, which killed 34.4%.

But this isn’t reason for succour because some of the biggest killers in the world today have low case fatality rates. The 2009 H1N1 pandemic, for example, saw case fatalities of less than 1%. But the virus infected so many people that it may have led to around 284,500 deaths worldwide, according to one estimate.

Also read: The Threat of Flu Pandemics is Real and India Needs a Vaccination Policy in Place Soon

The Wuhan epidemic definitely seems capable of fanning out fast. One way in which scientists estimate a virus’ ability to spread is by calculating its effective reproductive number: the number of new cases to whom each patient transmits the virus. And the 2019 nCoV’s reproductive number seems higher than SARS’s. According to an estimate published as a preprint paper, the Wuhan virus’ reproductive number is 2.9, compared to SARS’s 1.77 in the latter’s early days. Based on this calculation, the authors of the paper suggested that the 2019 nCoV has a “higher pandemic risk.” One reason for this discrepancy between SARS and the nCov could be the ability of the latter to spread asymptomatically, they said.

Won’t China’s quarantine measures prevent such a pandemic?

For sure, a lot is different in China this time compared to the 2003 SARS epidemic. That year, China indulged in a massive cover-up: it avoided reporting the outbreak to the WHO for 158 days, and took five months to announce it to the public. In this time, the virus made its way to several other countries.

This time, however, China publicly acknowledged the outbreak within a month, according to media reports. It also quickly published genome sequences of the viruses isolated from patients, allowing international researchers to analyse this data. But the country also seems to be overcompensating for its previous negligence, by deploying what may be unnecessarily stringent quarantine measures. It has imposed plane and train travel restrictions on some 45 million people in the Hubei province, of which Wuhan is the capital.

The effectiveness of such a massive quarantine will be strongly debated in the days to come. Quarantine measures can be a double-edged sword: on the one hand, they can slow the spread of an outbreak, but on the other, they can trigger panic and starve other public-health priorities of resources.

For example, even though both Beijing and Toronto imposed widespread quarantine measures during the SARS outbreak, experts later questioned their utility. Toronto in 2003 began isolating everyone who came in contact with SARS patients, a total of 23,103 people. These contacts were asked to remain indoors for 10 days, sleep away from their families and use separate utensils, even if they showed no symptoms.

Beijing did something similar but on a smaller scale. If Toronto targeted 100 people for every one patient, Beijing only isolated 12.

Other experts have subsequently argued that smaller quarantines would have worked just as well, without burdening health systems. According to one assessment published in the ‘Morbidity and Mortality Weekly’ report, Beijing could have contained SARS just by quarantining patients who were obviously sick because SARS does not spread asymptomatically. This would have led to 66% fewer people being isolated. As a bonus, healthcare workers would have been less stressed and non-emergency cases like cancer patients would not have been neglected, as they were.

If the 2019 CoV can spread asymptomatically, unlike SARS, this calculation may change. But even so, the current quarantine may have begun too late.

How late?

China imposed the quarantine on January 22, almost two months after the first patient in Wuhan showed symptoms. Subsequently, a virologist at California’s Scripps Research Institute used 27 genome sequences deposited by Chinese scientists into global gene banks to confirm the start date of the outbreak. By calculating the rate at which the virus was mutating, he estimated that the viruses had diverged from their most recent common ancestor (their common source) around December 2. This number is close to the date when China says the first symptoms arose, between December 1 and 8. This means two months have passed since the outbreak began – enough time for thousands of people to have left Wuhan.

Could China have moved faster? Perhaps. American infectious disease expert Daniel Lucey said in an interview to Science that the government likely knew more about the problematic nature of the virus than it let on. For example, until January 17, China maintained there was no person-to-person transmission. Instead, it claimed that most of the 41 patients in the first sick cluster had visited the Hunan Seafood Market, where live wild animals were sold. This led many to think that virus had jumped to each of the patients from animals in this market.

However, a paper published in The Lancet on January 24 raised doubts about this claim. The paper noted that 13 of the 41 patients had never visited the market, which means the virus had to be spreading from one person to another. China would have known this before the paper was published and yet it delayed acknowledgement.

Was the wet market the source for some patients at least?

It is hard to say. In a public notice on January18 , the Wuhan municipal commission did make it sound that way. Among the first steps China took to combat the outbreak was to close down the market. But the Lancet paper shows that the first patient to fall sick never visited the wet market. If so, he or she could have caught the virus elsewhere and then given it to others in the cluster.

Still, the virus does seem to have emerged from an animal source. One analysis reports that 96% of its genome is identical to a bat coronavirus, suggesting a bat origin. Yet another paper – this one more controversial – published last week argues that snakes were a likely source of the outbreak. This latter study examined the codons preferred by the 2019 nCoV to make proteins, and compared them to codons preferred by other species, like snakes, hedgehogs and bats.  Because the coronavirus’s preferred codons resembled those preferred by the Chinese krait and the Chinese cobra, the authors concluded that these species were most likely the animal hosts. But other scientists have questioned this theory for a number of reasons – including the fact that there is no previous instance of a cold-blooded reptile hosting a mammalian coronavirus.

If bats are the source, this wouldn’t be the first time. The Indian Nipah outbreak of 2018 was linked with fruit bats, although how the virus jumped to humans remains unclear. Wet markets – where a number of wild animal species are kept together in crowded, unhygienic conditions – are at major risk of such spillover events. For example, after the SARS outbreak, researchers hypothesised that live palm civets sold in Chinese restaurants could have given the virus to customers and attendants. The palm civet, in turn, may have acquired the virus from a bat.

As it happened with the SARS outbreak, the current one has also turned the spotlight onto China’s booming illegal trade in wild animals. One study in Southern China found that few people took precautions, like wearing masks and gloves, while purchasing animals from wet markets. After SARS, there were strong calls for Chinese markets to shut down the sale of live animals and to switch to refrigerated meat, which poses a lower risk of zoonotic spillover. But the strong demand from gourmands and traditional medicine practitioners has kept the business going, according to Reuters.

Priyanka Pulla is a science writer.